Share
Andrew Einhorn
Pelthos Therapeutics Inc., a biopharmaceutical company focused on bringing innovative therapies to patients with unmet medical needs, has appointed Andrew J. Einhorn to its Board of Directors.
Mr. Einhorn will serve as a director through Pelthos’ 2026 annual meeting of shareholders, or until his successor is duly elected and qualified, or until his earlier resignation or removal. In addition to joining the Board, he has also been appointed to the Audit Committee and the Compensation Committee.
Mr. Einhorn brings more than four decades of experience in corporate finance, investment banking, and capital markets, along with extensive leadership experience in C-level finance roles across clinical- and commercial-stage life science companies. His deep expertise in financial strategy, capital formation, and governance is expected to further strengthen Pelthos’ leadership as the company advances its therapeutic portfolio.
With Mr. Einhorn’s appointment, the Pelthos Board of Directors has expanded to eight members, reflecting the company’s continued commitment to building a strong and diverse governance structure. His addition enhances the Board’s financial and operational oversight capabilities during a critical phase of growth.
Currently, Mr. Einhorn serves as a consultant at Danforth Advisors, where he provides strategic financial guidance to both public and private life science companies. Prior to joining Danforth Advisors, he served as Chief Financial Officer at several biotechnology companies, including ESP Pharma, Esprit Pharma, Oceana Therapeutics, Edge Therapeutics, and RVL Pharmaceuticals, over a career spanning more than 20 years in the life sciences sector.
Earlier in his career, Mr. Einhorn spent more than two decades in capital markets and investment banking. He also currently serves as a venture advisor to the Israel Biotech Fund, further contributing to the advancement of the global biotechnology ecosystem.
